{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:20:02Z","timestamp":1788952802162,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11136-026-04317-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:44:20Z","timestamp":1781873060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cough, dyspnea, or chest pain? an examination of the composite endpoint in metastatic non-small cell lung cancer clinical trials"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-561X","authenticated-orcid":false,"given":"Carla","family":"Mamolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-0779","authenticated-orcid":false,"given":"Amparo Yovanna","family":"Castro Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"4317_CR1","unstructured":"Global Cancer Observatory: https:\/\/gco.iarc.fr\/en Accessed April 15, 2025"},{"key":"4317_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.9","author":"C Gridelli","year":"2015","unstructured":"Gridelli, C., Rossi, A., Carbone, et al. (2015). Non-small-cell lung cancer. Nature Reviews Disease Primers. https:\/\/doi.org\/10.1038\/nrdp.2015.9","journal-title":"Nature Reviews Disease Primers"},{"key":"4317_CR3","unstructured":"Lung Cancer Europe, 5th report on lung cancer: Psychological and social impact of lung cancer. November 2020. Report available on: www.lungcancereurope.eu"},{"key":"4317_CR4","unstructured":"U.S. Food and Drug Administration, The Voice of the Patient: Lung Cancer, 2013: https:\/\/www.fda.gov\/media\/130026\/download"},{"key":"4317_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"5","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 5, 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"key":"4317_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","volume":"5","author":"B Bergman","year":"1994","unstructured":"Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. European Journal of Cancer, 5, 635\u2013642.","journal-title":"European Journal of Cancer"},{"key":"4317_CR7","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.3390\/jcm12134371","volume":"12","author":"D Baracaldo-Santamaria","year":"2023","unstructured":"Baracaldo-Santamaria, D., Feliciano-Alfonso, J. E., Ramirez-Grueso, R., et al. (2023). Making sense of composite endpoints in clinical research. Journal of Clinical Medicine, 12, 4371\u20134385.","journal-title":"Journal of Clinical Medicine"},{"key":"4317_CR8","unstructured":"Health Technology Assessment Coordination Group. Guidance on outcomes for joint clinical assessments. Adopted June 2024. https:\/\/health.ec.europa.eu\/document\/download\/a70a62c7-325c-401e-ba42-66174b656ab8_en?filename=hta_outcomes_jca_guidance_en.pdf#page=19&zoom=100,90,201"},{"key":"4317_CR9","doi-asserted-by":"crossref","unstructured":"Fiero MH, Roydhouse JK, Bhatnagar V, et al. Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials. Lancet Oncol (2022): 23e229\u2013234.","DOI":"10.1016\/S1470-2045(22)00021-3"},{"issue":"150","key":"4317_CR10","first-page":"1","volume":"8","author":"K Cocks","year":"2024","unstructured":"Cocks, K., King-Kallimanis, B., Sims, J., et al. (2024). Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: Targeted literature review and best practice recommendations. Journal of Patient-Reported Outcomes, 8(150), 1\u201314.","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"4317_CR11","doi-asserted-by":"crossref","unstructured":"Perol, Pavlakis, Levchenko et al 2019 Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer. 138:79\u201387","DOI":"10.1016\/j.lungcan.2019.10.002"},{"key":"4317_CR12","unstructured":"Ceritinib (Zykadia) SmPC: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210114150422\/anx_150422_en.pdf"},{"key":"4317_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"10072","author":"J-C Soria","year":"2017","unstructured":"Soria, J.-C., Tan, D. S. W., Chiari, et al. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. The Lancet, 10072, 917\u2013929.","journal-title":"The Lancet"},{"key":"4317_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2022.11.004","volume":"174","author":"J Mazieres","year":"2022","unstructured":"Mazieres, J., Iadeluca, L., Shaw, et al. (2022). Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer, 174, 146\u2013156.","journal-title":"Lung Cancer"},{"issue":"3","key":"4317_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino, M. C., Shirish, G., Esteban, E., et al. (2020). Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(3), 387\u2013397.","journal-title":"The Lancet Oncology"},{"key":"4317_CR16","unstructured":"IMpower131 Clinical study report, data on file"},{"key":"4317_CR17","unstructured":"Poplar Clinical study report, data on file"},{"key":"4317_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.19.01348","volume":"3","author":"J Mazieres","year":"2020","unstructured":"Mazieres, J., Kowalski, D., Luft, et al. (2020). Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non\u2013small-cell lung cancer. Journal of Clinical Oncology, 3, 271\u2013280.","journal-title":"Journal of Clinical Oncology"},{"key":"4317_CR19","doi-asserted-by":"crossref","unstructured":"Shim A, Trone D, Reynolds M, et al. Patient-reported outcomes from a Phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Value in Health 25(2022):S42.","DOI":"10.1016\/j.jval.2022.09.2093"},{"key":"4317_CR20","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001."},{"key":"4317_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","volume":"188","author":"J Musoro","year":"2023","unstructured":"Musoro, J., Coens, C., & Sprangers, M. (2023). on behalf of EORTC Melanoma, Breast, Head and Neck, Genito-urinary, Gynecological, Gastro-intestinal Brain, Lung and Quality of Life Groups. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. European J Cancer., 188, 171\u2013182.","journal-title":"European J Cancer."},{"key":"4317_CR22","first-page":"69","volume":"24","author":"M Mukaka","year":"2012","unstructured":"Mukaka, M. (2012). A guide to appropriate use of correlation coefficient in medical research. Malawi Medical J, 24, 69\u201371.","journal-title":"Malawi Medical J"},{"key":"4317_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/medicina57050503","volume":"57","author":"T Monaghan","year":"2021","unstructured":"Monaghan, T., Rahman, S., Agudelo, C., et al. (2021). Foundational statistical principles in medical research: Sensitivity, specificity, positive predictive value, and negative predictive value. Medicina, 57, 503\u2013510.","journal-title":"Medicina"},{"key":"4317_CR24","unstructured":"Lung Cancer Europe, 6th report on lung cancer: Experiences and quality of life of people impacted by lung cancer in Europe. November 2021. Report available on: www.lungcancereurope.eu"},{"key":"4317_CR25","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E9 (R1) Statistical principles for clinical trials: addendum:estimands and sensitivity analyses in clinical trials. May 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04317-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:05:30Z","timestamp":1788951930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-026-04317-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4317"],"URL":"https:\/\/doi.org\/10.1007\/s11136-026-04317-6","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CM is an employee of Genentech Inc., a member of the Roche Group, and owns stocks\/shares in F. Hoffmann-La Roche Ltd. TH is a contractor of Genentech Inc., a member of the Roche Group. AYCS is an employee of F. Hoffmann-La Roche and has stocks\/shares in F. Hoffmann-La Roche Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"211"}}